Moderna, Inc.

MRNA · Nasdaq · ·

Karşılaştır

$223,22-%3,513 Kas kapanış

30 Eylül 2026 tarihine kadarki rakamlar, 6 Kasım 2026 tarihinde sunulan 10-Q raporundan

1W: -%12,2
1M: -%5,6

Moderna, Inc. (MRNA) hisse senedi — iyi bir şirket mi? — InspectStocks

Moderna, Inc.

MRNA · Nasdaq · ·

Karşılaştır

$223,22-%3,513 Kas kapanış

30 Eylül 2026 tarihine kadarki rakamlar, 6 Kasım 2026 tarihinde sunulan 10-Q raporundan

1W: -%12,2
1M: -%5,6

Just reported

Q3 2026 results

From Moderna's results release of 6 Kasım 2026; its quarterly report has since been filed.

Revenue
Actual
$1,31B
+%29 y/y
Guided
—
No guide given
EPS, GAAP
Actual
$0,38
Guided
—
No guide given
Operating income, GAAP
Actual
$130M
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Moderna is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Seçki
Biotech
InspectStocks tarafından · 19 companies
Drug developers with approved medicines, built mainly on biologic and genetic science.
Fiyat, 1 yıl
+%26,8
Gelir, 1 yıl
+%12,9
+13
A 8B 4C 5D 1F 1

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 352 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Nasıl para kazanıyor

COVID-19 vaccine sales, including Spikevax and mNEXSPIKE%93
Payments for manufacturing capacity%4
Government and other grants%1
Collaboration revenue%1
Licensing and royalties%1
RSV vaccine sales, including mRESVIA%0

Gelir payları year ended 2025-12-31 dönemi için tahmindir; resmî bir bildirimden alınmış rakamlar değildir.

Rekabet ettiği şirketler

Ne satıyor6

Spikevax
A COVID-19 vaccine updated to target circulating virus variants.
mNEXSPIKE
A COVID-19 vaccine that uses a lower mRNA dose than Spikevax and focuses the immune response on key parts of the virus.
mRESVIA
An RSV vaccine for older adults and certain adults at increased risk of severe RSV illness.

3 tane daha göster

mFLUSIVA
An influenza vaccine approved in the United States and Canada for adults aged 50 and older; commercial sales began in September 2026.
mCOMBRIAX
A vaccine combining protection against influenza and COVID-19, authorized in Europe and Canada for adults aged 50 and older; it had not been commercialized by September 30, 2026.
Intismeran autogene (mRNA-4157)
An investigational personalized cancer treatment designed around mutations in an individual patient's tumor; it is being developed with Merck alongside pembrolizumab.

Kim alıyor4

Wholesalers and distributors, which are the main route for sales in the United States.
Retail pharmacies, health care providers and government entities, which also buy vaccines in the United States.
Governments and international organizations that purchase vaccines.
Governments in the United Kingdom, Canada and Australia, which have multi-year commitments to purchase mRNA products.

Neye dayanıyor ve onu ne yıkabilir

Faaliyetin dayandığı şeyler

1COVID-19 vaccine sales made up 93.1% of revenue in 2025, tying revenue closely to demand for those vaccines.
2Vaccine sales are seasonal and depend on public health recommendations, changes in circulating viruses and whether people choose to get vaccinated.
3Some materials and manufacturing processes rely on single-source suppliers, and the company also uses outside manufacturers and suppliers.
4Intismeran autogene is being developed with Merck, with development costs and potential profits or losses generally shared equally.
5Vaccine products can require cold storage and careful shipping.

Ters gidebilecekler

1Demand for seasonal vaccines can change with public health recommendations, virus circulation, customer orders and willingness to vaccinate; these changes can affect sales.
2Clinical trials and regulatory reviews may delay or prevent approval of new vaccines and treatments; the influenza vaccine mRNA-1010 had faced a regulatory filing setback before its amended application was accepted for review.
3Manufacturing or supply problems, including supplier interruptions, product-release issues or failures to maintain required shipping and storage conditions, could delay or limit product supply.

Tüm finansal tablolar →

Moderna, Inc. hakkında

Moderna makes vaccines using messenger RNA (mRNA), which gives cells instructions to make a protein that can help prevent or treat disease. It also develops mRNA-based treatments, including a personalized cancer treatment being developed with Merck and treatments for rare inherited diseases. As of September 30, 2026, it had five approved products, though its flu-plus-COVID vaccine had not yet been commercialized.

Merkez: Cambridge, Massachusetts
Kuruluş: 2010
İşlem gördüğü borsa: Nasdaq
Mali yıl sonu: December 31

Moderna, Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.

Just reported

Q3 2026 results

From Moderna's results release of 6 Kasım 2026; its quarterly report has since been filed.

Revenue
Actual
$1,31B
+%29 y/y
Guided
—
No guide given
EPS, GAAP
Actual
$0,38
Guided
—
No guide given
Operating income, GAAP
Actual
$130M
Guided
—
No guide given